AI Article Synopsis
- The study aimed to pinpoint the most significant predictors of starting and continuing benzodiazepine (BZD) use by analyzing data from the Netherlands Study of Depression and Anxiety.
- Key findings indicated that insomnia, anxiety symptoms, receiving secondary care, and past BZD use were strong predictors for new users, while age, severe anxiety, and longer use duration were crucial for those continuing use.
- Positive life events were linked to a decreased likelihood of starting BZD, illustrating that mental health conditions greatly influence benzodiazepine usage patterns.
Article Abstract
Background: Longitudinal research on determinants of initiated and continued benzodiazepine (BZD) use is inconsistent and has identified many possible determinants. It is unclear which of those are most important in the prediction of BZD use. We aimed to identify the most important predictors of initiated and continued BZD use. Therefore, we analyzed the most consistently identified determinants from previous research plus some new determinants.
Methods: We identified baseline and 2-year longitudinal predictors of initiated BZD use (vs nonuse) among 2205 baseline BZD nonusers and of continued use (vs discontinued use) among 369 baseline BZD users in the Netherlands Study of Depression and Anxiety using logistic regression analyses.
Results: During follow-up, BZD use was initiated by 4.9% of BZD nonusers at baseline. Initiated use was predicted by insomnia (odds ratio [OR], 1.60), enduring anxiety symptoms (OR, 2.02), entering secondary care during follow-up (OR, 2.85), and past BZD use (OR, 3.57). Positive life events during follow-up reduced the likelihood of BZD initiation (OR, 0.76). Of BZD users at baseline, 54.2% continued use during the entire follow-up period. Continuation of BZD use was predicted by higher age (OR, 1.03), severe anxiety (OR, 1.85), and a long duration of BZD use (OR, 1.54). Leaving secondary care was associated with less continued BZD use (OR, 0.29).
Conclusion: Insomnia and anxiety were the main risk factors of initiated use, whereas advanced age and anxiety severity were the main risk factors of continued use. Sex, education, pain, and physical health seemed to be less important.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JCP.0b013e3182362484 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of benzodiazepines in patients with status epilepticus requiring second-line antiseizure medication treatment.
Epilepsy Res
January 2025
Department of Neurology, Vaasa Central Hospital, Vaasa, Finland.
Background: Status epilepticus (SE) is a life-threatening state that needs rapid and adequate treatment. Benzodiazepines (BZD) are used as a first-line treatment for SE, and if the desired effect is not achieved, second-line antiseizure medications are used.
Objective: To investigate whether the treatment with BZDs is performed adequately in patients with different subtypes of SE requiring second-line ASM treatment and, if not, to identify the factors influencing the suboptimal treatment.
Impact of 'street' benzodiazepines on drug-related deaths in England, Wales and Northern Ireland.
Drug Alcohol Rev
November 2024
Institute of Pharmaceutical Science, King's College London, London, UK.
Introduction: 'Street' benzodiazepines (BZD) are structurally and pharmacologically related to BZDs licensed for human use. In this study we investigated how street BZDs contribute to overall BZD use and death prevalences in England, Wales and Northern Ireland.
Methods: Data were analysed from deaths reported to the National Programme on Substance Use Mortality with post-mortem BZD detections (1999-2021), BZDs seized from music festivals (2017-2021) and drug samples with BZD detections submitted to Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS) (2017-2021).
High Dyspnea Score, a Trigger for Specialist Palliative Care Utilization-Results from a Cohort Study on the Predictors of High Opioid and Benzodiazepine Use in COVID-19 Patients.
J Palliat Med
November 2024
Department of Palliative Medicine, Tan Tock Seng Hospital, Singapore, Singapore.
Article Synopsis
- - Patients with severe COVID-19 often experience rapid worsening of symptoms, particularly dyspnea, necessitating early involvement of specialist palliative care (SPC) for effective symptom management and end-of-life care.
- - A study at the National Centre for Infectious Diseases in Singapore analyzed nonventilated COVID-19 patients between January 2021 and July 2022 to identify risk factors for high use of opioids and benzodiazepines in managing dyspnea.
- - Findings revealed that patients with higher dyspnea scores and lower ISARIC-4C mortality scores were more likely to be high users of these medications, indicating they have increased oxygen needs and higher mortality rates, thus highlighting the need for timely
Systematic review of Buzhong Yiqi method in alleviating cancer-related fatigue: a meta-analysis and exploratory network pharmacology approach.
Front Pharmacol
November 2024
The Thyroid and Breast Surgery Department, Ma'anshan City People's Hospital, Ma'anshan, China.
Article Synopsis
- The study aims to evaluate the effectiveness of the Buzhong Yiqi prescription in treating cancer-related fatigue (CRF) through meta-analysis and network pharmacology methods.
- It focuses on randomized controlled trials (RCTs) involving various cancer patients and compares the Buzhong Yiqi treatment with conventional options, ensuring comprehensive data collection from multiple databases.
- The evaluation of treatment efficacy was based on established quality-of-life measures and involved identifying the active ingredients in Buzhong Yiqi to understand its therapeutic mechanisms.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!